Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FluMos-v1 Phase I in Healthy Adults
NCT04896086Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2021
- Primary completion
- Jan 2024
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of FluMos-v1 in seasonal influenza (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms at 7 days, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms at 7 days and 5 more. Started May 2021; status: completed.
02
Drugs
FluMos-v1
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT04896086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04896086.